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Abstract
The identification of CYP2C9 and VKORC1 genes has strongly stimulated the research on pharmacogenetics of coumarins in
the last decade. We assessed the combined influence of CYP2C9 *2 and *3, and VKORC1 c.-1639G.A, 497C.G, and
1173C.T variants, on acenocoumarol dosage using a novel algorithm approach, in 193 outpatients who had achieved
stable anticoagulation. We constructed an ‘‘acenocoumarol-dose genotype score’’ (AGS, maximum score=100) based on
the number of alleles associated with higher acenocoumarol dosage carried by each subject for each polymorphism. The
mean AGS was higher in the high-dose (.28mg/week) compared with the low-dose (,7mg/week) group (mean(SEM) of
84.163.4 vs. 62.264.8, P=0.008). An AGS.70 was associated with an increased odds ratio (OR) of requiring high
acenocoumarol dosage (OR: 3.347; 95%CI: 1.112–10.075; P=0.032). In summary, although more research is necessary in
other patient cohorts, and this algorithm should be replicated in an independent sample, our data suggest that the
AGS algorithm could be used to help discriminating patients requiring high acenocoumarol doses to achieve stable
anti-coagulation.
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Introduction
Oral anticoagulant therapy with vitamin K antagonists (couma-
rins) is used worldwide for the treatment and prevention of
thrombotic diseases. The clinical use of oral anticoagulant therapy
is complicated by narrow therapeutic range and the large inter-
individual variation that exists in response to the same dosage.
While an insufficient dose may fail to prevent thromboembolism,
an overdose increases the risk of serio u sa d v e r s ee f f e c t ss u c ha si n t r a -
cerebral bleeding. Although several factors including gender, age or
race have been traditionally considered to explain individual
variability in coumarin dosage needed to achieve stable and effective
anticoagulation, growing evidence supports the influence of genetic
factors [1]. The identification of the genes encoding cytochrome P-
450 2C9 enzyme (CYP2C9), the principal metabolizing enzyme of the
coumarins, and vitamin K epoxide reductase enzyme (VKORC1), the
molecular target for coumarins, has strongly stimulated the research
on pharmacogenetics of coumarins in the last decade. Several
variants in CYP2C9 (CYP2C9*2 and especially the CYP2C9*3 allele)
and VKORC1 genes (especially the 1639G.Ap o l y m o r p h i s m )
are associated with effective coumarin derivative dose
[2,3,4,5,6,7,8,9,10,11]. CYP2C9 and VKORC1 seem the only genes
with relevant effects on coumarin response [10], except the rs2108622
polymorphism in the gene encoding cytochrome P450, family 4,
subfamily F, polypeptide 2 (CYP4F2) which could also influence
warfarin dose [9]. This enables to set the definitive demarcation of the
genetic information that is needed for developing useful coumarin
dosing algorithms. With regards to this, a simple recent algorithm to
account for the putative influence of several gene variants, and of the
complex interaction between these variants, on a given phenotype is
the so-called ‘total genotype score’ (TGS). For instance, Kathiresan
et al [12] recently computed a TGS of nine validated genotypes
associated with modulation in blood lipid levels. They showed that the
polygenic profilethey obtained with the TGS was an independent risk
factor for incident cardiovascular disease [12].
The purpose of our study was to assess the combined influence
of several variants alleles of the CYP2C9 (*2 and *3) and VKORC1
(c.-1639G.A, 497C.G, and 1173C.T) polymorphisms, using
the TGS approach, on the acenocoumarol dosage needed to
achieve stable, effective anticoagulation. We chose the aforemen-
tioned gene variants based on their high frequency among
Caucasians [13] and on previous research showing their
association with acenocoumarol dose [2]. Briefly, the risk of
requiring a low dose of acenocoumarol is significantly higher in
patients carrying at least one CYP2C9*3 allele, and the KVORC1
genotypes c.-1639 AA, 497 CG and GG, and 1173 TT [2].
Results
The genotype frequencies of CYP2C9 and VKORC1 genes for
the three study groups (low-, medium- and high-dose) are shown in
Table 1. The distribution of individuals in the low-, medium- and
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metabolism for 0 up to 5 polymorphisms is shown in Table 2.
The mean AGS was significantly higher (P=0.008) in the high-
dose group compared with the low-dose group (Figure 1). A total
of five (29.4%) individuals in the high-dose group had an AGS of
100, versus 2 (6.1%) and 20 (14.3%) in the low- and medium-dose
groups respectively. A total of 21 patients per group (high-dose and
low-dose group, n=42 in total) would have been needed in order
to demonstrate statistically significant between-group differences in
AGS, with a power of 95% and a of 0.05.
The ROC analysis showed a significant discriminating accuracy
of AGS in identifying an individual with low-dose (AUC=0.630;
95%CI: 0.557–0.699, P=0.009; sensitivity=0.668, specifici-
ty=0.545) and high-dose (AUC=0.676; 95%CI: 0.605–0.742,
P=0.017; sensitivity=0.583, specificity=0.706). The correspond-
ing AGS cut-off value for low-dose was #60, and for high-dose
.70. Logistic regression analysis showed that subjects with AGS
#60 had an increased odds ratio (OR) of being in a need of low-
dose of acecoumarol (OR: 2.356; 95%CI: 1.094–5.073; P=0.028),
whereas subjects with AGS .70 had an increased odds ratio (OR)
of being in a need of high-dose of acecoumarol (OR: 3.347;
95%CI: 1.112–10.075; P=0.032). The results did not change after
controlling for drugs that can interfere with the anticoagulant
effect of acenocoumarol (data not shown).
Discussion
This is the first report assessing the cumulative effects of CYP2C9
and VKORC1 variants on the coumarine dose needed to achieve
stable anticoagulation using a novel simple algorithm approach,
which we labeled ‘AGS’. This method was especially useful to
predict outlier patients needing high doses (OR=3.3347 for those
with AGS.70).
The question addressed here is of clinical relevance. Coumarin
anticoagulants are among the most widely prescribed drugs. A
difficulty with their use is that dosage needs to be individually
determined for each patient, usually by following a standard initial
dosing protocol and measuring the coagulation rate (e.g., the INR)
regularly. Although the current oral coumarin anticoagulants
(warfarin, acenocoumarol and phenprocoumon) are likely to be
replaced by other drugs, such as specific thrombin inhibitors, the
coumarins will probably continue to be the main oral anticoag-
ulants prescribed in the short-medium term. Thus, understanding
the factors that can explain individual variability in the coumarin
dosage needed to achieve stable anticoagulation is of medical
interest. Genetics is one of such factors. In fact, the US Food and
Drug Administration recently included reference to CYP2C9 and
VKORC1 in the prescription information on warfarin [17].
The combined influence of CYP2C9 and VKORC1 genotypes
accounts for as much as ,30% of the variability in coumarin dose
requirement [1]. Thus, there is currently intense debate as to
whether pharmacogenetic algorithms for estimating the dose of
coumarins provide a more accurate dose than the fixed-dose
approach that is commonly used worldwide [1]. It has also been
suggested that the greatest benefit of pharmacogenetic algorithms
is observed in patients with extreme dose requirements [8]. With
regards to this, the AGS value was significantly higher in our high-
dose (.28mg/wk) compared with the low dose group (,7mg/wk),
with the ROC analysis showing an AGS cut-off value for low-dose
of #60, and for high-dose .70. It is also noteworthy that the
Table 1. Genotypes of CYP2C9 and VKORC1 genes, genotype score (GS) for each polymorphism, and acenocoumarol dose.
Gene Polymorphism GS Low-dose (%) Medium-dose (%) High-dose (%)
CYP2C9 (Cytochrome P-450 2C9) CYP2C9*2 or 430C.T (rs1799853) 0=TT, 1=CT, 2=CC 0, 32.4, 67.6 2.8, 33.3, 63.8 5.6, 11.1, 83.3
CYP2C9*3 or 1075A.C (rs1057910) 0=CC, 1=AC, 2=AA 14.7, 29.4, 55.9 1.4, 15.6, 83.0 0, 0, 100
VKORC1 (Vitamin K epoxide
reductase)
c.-1639G.A (rs9923231) 0=AA, 1=GA, 2=GG 38.2, 35.3, 26.5 21.3, 44.7, 34.0 5.6, 44.4, 35.0
497T.G (rs2884737) 0=GG, 1=TG, 2=TT 15.2, 39.4, 45.5 10.0, 39.3, 50.7 5.9, 29.4, 64.7
1173C.T (rs9934438) 0=TT, 1=CT, 2=CC 23.5, 35.3, 41.2 14.2, 46.8, 39.0 5.6, 44.4, 50.0
The group comparisons of genotypic and allelic frequency of these polymorphisms have been published elsewhere [2].
Values of GS: 0=very slow metaboliser (low dose), 1=slow metaboliser (medium dose), and 2=normal metaboliser (high dose).
doi:10.1371/journal.pone.0011210.t001
Table 2. Distribution of individuals in the low-, medium- and
high-dose groups with genotypes of very low, low and normal
metabolism for 0 up to 5 polymorphisms.
Number of
genotypes
Low-dose
(n=34)
Medium-dose
(n=142)
High-dose
(n=18)
P
value
Very low
0 50.0 (17) 73.8 (104) 83.3 (15) 0.005
1 20.6 (7) 10.6 (15) 11.1 (2)
2 17.6 (6) 8.5 (12) 5.6 (1)
3 11.8 (4) 6.4 (9) 0
4 0 0.7 (1) 0
50 0 0
Low
0 22.0 (8) 22.0 (31) 33.3 (6) 0.242
1 23.5 (8) 26.2 (37) 22.2 (4)
2 23.5 (8) 17.7 (25) 27.8 (5)
3 17.6 (6) 19.9 (28) 16.7 (3)
4 11.8 (4) 12.8 (18) 0
5 0 1.4 (2) 0
Normal
0 2.9 (1) 1.4 (2) 0 (0) 0.006
1 32.4 (11) 21.3 (30) 5.6 (1)
2 20.6 (7) 29.8 (42) 22.2 (4)
3 20.6 (7) 14.9 (21) 22.2 (4)
4 17.6 (6) 18.4 (26) 22.2 (4)
5 5.9 (2) 14.2 (20) 27.8 (5)
Values are % (n).
doi:10.1371/journal.pone.0011210.t002
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(N=27) with an AGS of 100, vs. 14.5mg/wk in the rest of
participants.
Our study is not without potential limitations. Besides the small
sample size of our cohort, our findings are limited, at least partly,
by the fact that it was not possible to replicate our data in a
different cohort of patients, particularly using a prospective design
with patients recruited at the start of their treatment. To increase
the applicability of genetic algorithms as the one proposed here,
further research should study large population cohorts, and
include different ethnic groups.
In summary, while recognizing the need for more research in
this area, we propose that, in those settings where genomics tool
are routinely applied, the AGS algorithm could be used to help
discriminating patients requiring high acenocoumarol doses to
achieve stable anti-coagulation (vs. those requiring low doses), and
thus to prevent the serious risks associated with insufficient drug
use.
Methods
The study comprised 193 outpatients [100 men and 93 women;
mean (SEM) age: 64 (1) yr]. They all had achieved a stable
anticoagulation state at the moment of entering the study (after
receiving oral anticoagulant therapy with acenocoumarol within
the previous 6+ months), i.e. target INR of 3.0–4.0 in patients with
a prosthetic heart valve and of 2.0–3.0 for the rest of patients.
They were free of any concomitant severe disease known to
interfere with acenocoumarol treatment [2].
We extracted genomic DNA from peripheral EDTA-treated
anti-coagulated blood to genotype: (i) CYP2C9 *2 and *3, and
VKORC1 3730G.A using real-time polymerase chain reaction
(PCR) followed by melting curve analysis with fluorescence
resonance energy transfer probes; and (ii) VKORC1 polymorphisms
c.-1639G.A, 497C.G, and 1173C.T with specific PCR
followed by single base extension using capillary electrophoresis
[2]. The study was approved by our institutional committee
(Universidad Europea de Madrid, Spain) and all participants provided
their written informed consent.
We computed the combined influence of all the five studied
polymorphisms following the TGS method described elsewhere
[14,15]. First, we scored each genotype within each polymorphism
(Table 1). We assumed an additive model (equaling 0, 1 or 2), that
is, on the basis of the number of alleles associated with higher
acenocoumarol dosage that were carried by each subject for each
polymorphism (Table 1). Thus, we assigned a genotype score (GS)
of 2, 1 and 0 to each individual genotype associated with highest,
medium and lowest acenocoumarol dose respectively. For
instance, a GS of ‘2’ was given for the wild type (CC) genotype
of the CYP2C9 *2 allele (i.e. ‘normal metaboliser’, associated with
highest drug dose) vs. a GS of ‘1’ for the CT genotype (‘slow
metaboliser’, medium dose), and a GS of ‘0’ for the TT genotype
(‘very slow metaboliser’, lowest dose).
Second, we summed the GS of each single genotype (GSCYP2C9 *2
+ GSCYP2C9 *3 + GSVKORC1 c.-1639G.A + GS VKORC1 497C.G +
GS VKORC1 1173C.T), which allowed us to construct an ‘acenocou-
marol-dose genotype score’ (AGS).
Third, the obtained AGS was ‘normalised’ (i.e. transformed to
the scale of 0–100) for easier interpretation, as follows:
AGS=(100/10)6 (GSCYP2C9 *2 + GSCYP2C9 *3 + GSVKORC1 c.-1639G.A +
GS VKORC1 497C.G+GS VKORC1 1173C.T)[14,15],where 10 is the result of
multiplying 5 (number of studied polymorphisms) by 2, which is the
score given to the genotype associated with the highest drug dose.
AnAGSof100representsthetheoretically highestpossible scorefor
the polygenic profile of acenocoumarol dose, that is, that all GS are
2. In contrast, an AGS of 0 represents the theoretically ‘less
acenocoumarol-dose dependent’ profile.
Statistical analysis
We compared the AGS means among groups of low-, medium-
and high-acenocoumarol dose with one-way analysis of covariance,
where AGS was entered as a dependent variable, group (low-,
medium-, and high-dose) as fixed factor, and sex and age as
covariates. We used Bonferroni post hoc test for between-group
comparisons. We repeated the analysis after further controlling for
drugs that can interfere with the anticoagulant effect of acenocou-
marol,i.e.ACEinhibitors,angiotensinIIreceptorantagonists,statins,
beta-blockers, Ca
2+ antagonists, anti aggregants, digoxin, valproic
acid, anticonvulsant drugs that are enzymatic inductors (phenytoin,
carbamazepine and phenobarbital) and amiodarone.
We compared the distribution of individuals in the low,
medium- and high-dose groups with genotypes of very slow, slow
and normal metabolism for 0 up to 5 polymorphisms by using the
x
2 test. The ability of the AGS to correctly classify individuals in
the high-dose group (coded as 1) from those in the low- or
medium-dose (coded as 0) was analyzed by receiver operating
characteristic (ROC) curves [16]. Similarly, we repeated the same
procedure to study the diagnostic value of the AGS on identifying
individuals in the low-dose (coded a 1) group from those in the
medium- or high-dose (coded as 0). We calculated the area under
the ROC curve (AUC) and 95% confidence intervals (95%CI).
Finally, we used binary logistic regression to study the relationship
between AGS and low or high dose.
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